Collocation of metformin and dipeptidyl peptidase-4 inhibitor is associated with increased risk of diabetes-related vascular dementia: A single hospital study in Northern Taiwan

Recent studies have established a close link between diabetes mellitus (DM) and an increased risk of vascular dementia (VD). In this study, we evaluated the risk of VD in patients with type 2 diabetes who were on antidiabetic medications. There is a growing interest in observational and data-driven...

Full description

Saved in:
Bibliographic Details
Published inExpert opinion on investigational drugs Vol. 32; no. 2; p. 171
Main Authors Tzeng, I-Shiang, Hsieh, Tsung-Han
Format Journal Article
LanguageEnglish
Published England 01.02.2023
Subjects
Aged
Dementia, Vascular - chemically induced
Dementia, Vascular - etiology
Diabetes Mellitus, Type 2 - complications
Diabetes Mellitus, Type 2 - drug therapy
Dipeptidyl-Peptidase IV Inhibitors - adverse effects
Hospitals
Humans
Hypoglycemic Agents - adverse effects
Metformin - adverse effects
Middle Aged
Taiwan - epidemiology
Taiwan
metformin
risk factors
diabetes mellitus
Vascular dementia
dipeptidyl peptidase 4 inhibitors
Online AccessGet more information

Cover

More Information
Summary:Recent studies have established a close link between diabetes mellitus (DM) and an increased risk of vascular dementia (VD). In this study, we evaluated the risk of VD in patients with type 2 diabetes who were on antidiabetic medications. There is a growing interest in observational and data-driven studies to answer specific research questions for defined populations. In line with this, 67,281 patients (age range, 61.95 ± 13.88 years; length of follow up, 3.2 ± 3.4 years) diagnosed with DM were divided into two groups:48,072 subjects who had not used dipeptidyl peptidase-4 (DPP-4) medication and 19,209 subjects who had taken DPP-4 medication. Each patient underwent follow-up examination after the date of the latest diagnosis. Among 10,884 DM patients with dementia, the combination therapy of metformin and DPP-4 inhibitor may increase the risk of dementia compared with that in the control group (adjusted hazard ratio, 1.11; 95% confidence interval, 1.06-1.15; p ≤ 0.001). In this study, patients who received a combination therapy of metformin and DPP-4 inhibitor for DM were at a higher risk of dementia than those who received monotherapy.
ISSN:1744-7658
DOI:10.1080/13543784.2023.2178417